Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Management and outcomes in second and/or third relapse in patients with multiple myeloma in the real-life setting: EMMY study results.
Thomas Chalopin, MD (he/him/his)
Hematologist
Department of Hematology and Cell Therapy, Tours University Hospital, Tours, France, France